Neurol India. 2025 May 1;73(3):488-494. doi: 10.4103/neuroindia.NI_1615_20. Epub 2025 May 23.
ABSTRACT
BACKGROUND: Neuroinflammation is a key feature of Alzheimer’s disease (AD) pathology.
OBJECTIVES: The aim of this study was to investigate the serum levels of Cytokine 6 (Cyto-6), Cytokine 10 (Cyto-10), and alpha-tumor necrosis factor (α-TNF) in Alzheimer’s disease patients and observe the effects of donepezil plus vitamin B12 (VB12) treatment on these cytokines.
METHODS AND MATERIALS: Seventy-one AD cases and 70 controls with age more than 60 years. Cyto-6, Cyto-10, and α-TNF were measured using the Chemiluminescence Immulite 1000 system, Siemens. Alzheimer’s disease subjects were treated with donepezil (5 mg/day) plus VB12 (1.5 mg/day) supplement for 6 months, and serum cytokine levels were reinvestigated. Statistical analysis was done using SPSS software.
RESULT: Cyto-6, Cyto-10, and α-TNF values were raised in Alzheimer’s disease as compared to controls (P < 0.001) [AD (Cyto-6: 10.27 ± 2.76 pg/ml; Cyto-10: 6.2 ± 1.48 pg/ml; α-TNF: 26.49 ± 6.85 pg/ml) and Control (Cyto-6: 3.29 ± 0.77 pg/ml; Cyto-10: 8.213 ± 0.787 pg/ml; α-TNF: 5.18 ± 1.65 pg/ml)]. After 6 months, a significant decrease (P < 0.01) was observed in Cyto-6 (7.95 ± 2.21 pg/ml), Cyto-10 (4.77 ± 1.12 pg/ml), and α-TNF (22.67 ± 7.00 pg/ml) levels in AD.
CONCLUSION: We conclude that serum Cyto-6, Cyto-10, and α-TNF play an inflammatory role in Alzheimer’s disease progression. Combined therapy of donepezil and VB12 supplement showed a beneficial effect in reducing inflammation. This study might benefit further research along with molecular follow-up studies for development of novel therapeutic strategies in Alzheimer’s disease.
PMID:40408576 | DOI:10.4103/neuroindia.NI_1615_20
